Fasudil with immunotherapy for advanced prostate cancer
Part of Cancer, Kidney & urinary clinical trials.
This trial tests a combination of fasudil hydrochloride and immunotherapy for men with metastatic castration-resistant prostate cancer that has stopped responding to chemotherapy and hormone therapy. The goal is to see if this new approach can help control the cancer.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 to 84 years old.
- You have metastatic castration-resistant prostate cancer that has spread to bones or other organs.
- You have tried at least one chemotherapy with docetaxel and one newer hormone therapy, and these treatments no longer work.
- Your PSA level is rising, and you have new or growing tumors on scans.
- You are in generally good health, with expected survival of at least 3 months.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a treatment that uses high-intensity focused ultrasound to target and destroy cancer cells in the prostate, combined with a newer hormone therapy. This approach may help control advanced prostate cancer and improve outcomes.
This trial tests a combination of high-dose testosterone with enzalutamide and difluoromethylornithine (DFMO) for men whose prostate cancer has spread and stopped responding to standard hormone therapy. It aims to see if this approach can shrink tumors or slow the cancer's growth.
This trial tests a combination of hormone therapy, chemotherapy (docetaxel), and a targeted drug (apalutamide) with a focused ultrasound procedure (HIFU) for men with prostate cancer that has spread to many bones or organs. It may help control the cancer more effectively.
This study combines two treatments: pembrolizumab, which helps your immune system fight cancer, and a targeted radioactive medicine (177Lu-PSMA-617) that seeks out and damages prostate cancer cells. It may help men whose prostate cancer has spread despite initial hormone therapy.
This study tests whether adding a diabetes drug called dapagliflozin to standard hormone therapy can help control advanced prostate cancer better than hormone therapy alone. It may slow cancer growth and improve outcomes.
This trial tests a new combination of drugs given before surgery for locally advanced prostate cancer. The goal is to see if giving these drugs first helps shrink the tumor and improves outcomes after surgery.
Hear when a new Prostate cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.